Kronos Bio (NASDAQ:KRON) Given New $2.50 Price Target at HC Wainwright

Kronos Bio (NASDAQ:KRON – Free Report) had its price target cut by HC Wainwright from $9.00 to $2.50 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. Separately, Piper Sandler dropped their price objective on Kronos Bio from $7.00 to $6.00 and set an […]

Related Keywords

Switzerland ,Swiss ,Kronos Bio ,Norbertw Bischofberger ,Piper Sandler ,Kronos Bio Inc ,Geode Capital Management ,Securities Exchange Commission ,Kronos Bio Company Profile ,Swiss National Bank ,Acadian Asset Management ,Free Report ,Get Free Report ,Exchange Commission ,National Bank ,Asset Management ,Capital Management ,Rhumbline Advisers ,Kronos Bio Daily ,Nasdaq Kron ,Akron ,Medical ,Lower Price Target ,Hc Wainwright ,